Latest Drugs, Latest Approval in MTOR inhibitors

What are MTOR inhibitors?

Mammalian target of rapamycin (mTOR) inhibitors block the activity of the mammalian target of rapamycin. Mammalian target of rapamycin is a protein kinase, which regulates growth factors that stimulate cell growth and angiogenesis. In certain cancers the mTOR pathway is more active.

Mammalian target of rapamycin (mTOR) inhibitors are used in treatment of renal cancer and is being studied for use in other types of cancers. More benefits are being seen when MTOR inhibitors are combined with other chemotherapy agents.

Name Updated
Sirolimus (Sirolimus [ sih-ro-lim-us ]) 15-Aug-2023
Sirolimus topical (Sirolimus topical [ sir-oh-li-mus ]) 14-Aug-2023
Sirolimus protein-bound (Sirolimus protein-bound [ sir-oh-li-mus-proe-teen-bownd ]) 14-Aug-2023
Temsirolimus (Temsirolimus [ tem-sir-oh-li-mus ]) 12-Aug-2023
Everolimus (Everolimus) 11-Aug-2023
Torisel (Temsirolimus [ tem-sir-oh-li-mus ]) 05-Aug-2023
Afinitor disperz (Everolimus (afinitor) [ e-ver-oh-li-mus ]) 04-Aug-2023
Zortress (Everolimus (zortress) [ e-ver-oh-li-mus ]) 14-Jul-2023
Hyftor (Sirolimus) 13-Jul-2023
Rapamune (Sirolimus [ sih-ro-lim-us ]) 11-Jul-2023
Afinitor (Everolimus) 10-Jul-2023